LGT Fund Management Co Ltd. Trims Position in Pfizer Inc. $PFE

LGT Fund Management Co Ltd. lessened its position in shares of Pfizer Inc. (NYSE:PFE) by 47.1% in the second quarter, Holdings Channel reports. The fund owned 23,050 shares of the biopharmaceutical company’s stock after selling 20,500 shares during the quarter. LGT Fund Management Co Ltd.’s holdings in Pfizer were worth $559,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently bought and sold shares of the company. QRG Capital Management Inc. increased its position in Pfizer by 8.6% during the second quarter. QRG Capital Management Inc. now owns 759,903 shares of the biopharmaceutical company’s stock valued at $18,420,000 after acquiring an additional 59,948 shares during the last quarter. Corundum Group Inc. grew its holdings in Pfizer by 3.0% during the second quarter. Corundum Group Inc. now owns 32,175 shares of the biopharmaceutical company’s stock valued at $780,000 after purchasing an additional 934 shares during the period. Franklin Street Advisors Inc. NC grew its holdings in Pfizer by 27.0% during the second quarter. Franklin Street Advisors Inc. NC now owns 54,831 shares of the biopharmaceutical company’s stock valued at $1,329,000 after purchasing an additional 11,668 shares during the period. Stock Yards Bank & Trust Co. grew its holdings in Pfizer by 0.6% during the second quarter. Stock Yards Bank & Trust Co. now owns 93,054 shares of the biopharmaceutical company’s stock valued at $2,256,000 after purchasing an additional 551 shares during the period. Finally, HighMark Wealth Management LLC grew its holdings in Pfizer by 123.7% during the second quarter. HighMark Wealth Management LLC now owns 4,249 shares of the biopharmaceutical company’s stock valued at $103,000 after purchasing an additional 2,350 shares during the period. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Price Performance

NYSE:PFE opened at $27.37 on Friday. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. The company has a market capitalization of $155.59 billion, a P/E ratio of 14.56, a P/E/G ratio of 0.88 and a beta of 0.55. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $30.43. The business’s 50-day moving average is $24.67 and its 200 day moving average is $24.14.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. The company had revenue of $14.65 billion for the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The firm’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same period in the previous year, the business earned $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, equities research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts have issued reports on the company. Citigroup boosted their price target on Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a report on Wednesday, August 6th. Weiss Ratings reissued a “hold (c-)” rating on shares of Pfizer in a report on Saturday, September 27th. UBS Group reissued a “neutral” rating and set a $28.00 price target on shares of Pfizer in a report on Wednesday. Wall Street Zen lowered Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, September 28th. Finally, Bank of America upped their price objective on Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a research note on Friday. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $28.41.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.